⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19593064 | 1.00 | — | — | |
| SCHEMBL13406769 | 0.73 | — | — | |
| SCHEMBL2606457 | 0.72 | — | — | |
| SCHEMBL1244002 | 0.72 | — | — | |
| SCHEMBL2606459 | 0.72 | — | — | |
| SCHEMBL21131962 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL19086802 | 0.69 | — | — | |
| SCHEMBL9130423 | 0.69 | — | — | |
| SCHEMBL582319 | 0.69 | — | — | |
| SCHEMBL23254944 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210346326-A1 | COMPOSITIONS AND METHODS FOR ALTERING NEUTROPHIL MIGRATION AND METASTASIS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2021-11-11 | — | — | US | disclosed |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |